ATP11C

Across TCGA pan-cancer cohorts, ATP11C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP11C data layer compared with 20 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ATP11C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP11C expression acts as an unfavorable survival marker.

GBM, CCRCC, and LUAD are the cancer types where ATP11C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.272	0.463	.001	18	view →
CCRCC	DFS	Tertile	IV	0.322	1.000	.036	4	view →
LUAD	OS	Quartile	II,III,IV	0.503	0.814	.038	2	view →
LSCC	DFS	Median	II,III,IV	0.444	0.883	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP11C–GBM (DFS)

Open the GBM breakdown →